Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NanoViricides, Inc. Common Stock (NY:NNVC)

1.160 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
Via Investor Brand Network
Topics Intellectual Property World Trade
Exposures COVID-19 Intellectual Property Tariff
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
Via ACCESS Newswire
NanoViricides, Inc. Has Filed its Quarterly Report
Via ACCESS Newswire
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
Via ACCESSWIRE
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
Via Investor Brand Network
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Engages CRO for Phase II Clinical Trial
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides President Dr. Diwan to Present at the PODD Conference
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.